Menu
← Oncology Approval Tracker
FDA DECISION ·
Avzivi
bevacizumab-tnjn · Bio-Thera Solutions
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
A bevacizumab biosimilar for labeled uses in metastatic colorectal and renal cell cancer, first-line nonsquamous NSCLC, recurrent glioblastoma, persistent or recurrent or metastatic cervical cancer, and platinum-resistant recurrent ovarian, fallopian tube or primary peritoneal cancer. Specific regimens and treatment-line limits vary by use.
LAMPGEN ANALYSIS
Why it matters
This action added a biosimilar product for several established VEGF-inhibition regimens.
What research teams should watch
Reconcile the original approved indications and institutional formulary before using the biosimilar in a regimen or study.
PRIMARY RECORDS